{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Aurinia Pharmaceuticals, Inc.
Aurinia Pharmaceuticals Hits Day High with 8.66% Surge in Stock Price
Aurinia Pharmaceuticals has shown strong stock performance, gaining 8.66% on October 31, 2025, and outperforming the S&P 500 over the past year. The company reported a 12.08% increase in net sales and positive results for five consecutive quarters, reflecting robust operational strength and effective capital utilization.
Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?
As of October 17, 2025, Aurinia Pharmaceuticals is fairly valued with a P/E ratio of 19 and an EV to EBITDA of 11.23, outperforming the S&P 500 with a 60.86% return over the past year, despite a higher P/E compared to some peers.
Aurinia Pharmaceuticals Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics
Aurinia Pharmaceuticals has recently adjusted its valuation, showcasing a P/E ratio of 19 and a price-to-book value of 3.16. The company has achieved a 60.86% return over the past year, outperforming the S&P 500, while its three-year return of 53.39% lags behind the index.
Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?
As of October 17, 2025, Aurinia Pharmaceuticals is fairly valued with a P/E ratio of 19, strong profitability metrics, and a 60.86% return over the past year, outperforming the S&P 500.
Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?
As of October 17, 2025, Aurinia Pharmaceuticals is fairly valued with a P/E ratio of 19 and a year-to-date return of 28.62%, outperforming the S&P 500, but its long-term 5-year return of -25.44% indicates potential challenges compared to the S&P's 91.29% return.
Aurinia Pharmaceuticals Experiences Revision in Score Amid Strong Financial Metrics and Market Position
Aurinia Pharmaceuticals has adjusted its valuation, showcasing strong financial metrics such as a high return on capital employed and favorable P/E ratio compared to peers. The company has outperformed the S&P 500 over the past year, indicating its competitive strength in the Pharmaceuticals & Biotechnology sector.
Aurinia Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance
Aurinia Pharmaceuticals, Inc. has recently adjusted its technical trends, with its stock price at $11.32. Over the past year, the company has achieved a 58.99% return, significantly surpassing the S&P 500. Technical indicators suggest a bullish outlook, despite some short-term volatility in returns.
Is Aurinia Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Aurinia Pharmaceuticals has a mildly bullish trend, with strong short-term performance but underperformance over the past three to five years compared to the S&P 500.
Is Aurinia Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Aurinia Pharmaceuticals has a mildly bullish technical trend, with mixed performance indicators and recent underperformance compared to the S&P 500, although it has outperformed year-to-date and over the past year.
Is Aurinia Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Aurinia Pharmaceuticals has a mildly bullish technical trend, supported by bullish MACD and KST indicators, despite a year-to-date return of 26.39% that outperforms the S&P 500 but lags over the long term.
Aurinia Pharmaceuticals Hits Day Low of $11.04 Amid Price Pressure
Aurinia Pharmaceuticals, Inc. faced a notable decline in stock value today, contrasting with the S&P 500's modest gain. Despite recent setbacks, the company has demonstrated strong annual growth and solid financial metrics, including significant net sales growth and a high interest coverage ratio, indicating robust operational performance.
Aurinia Pharmaceuticals Hits New 52-Week High of $13.44, Up 142%
Aurinia Pharmaceuticals has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals sector with a notable increase over the past year. The company has shown solid financial metrics, including a significant growth in net sales and a high interest coverage ratio, indicating robust financial health.
Aurinia Pharmaceuticals Hits New 52-Week High of $13.05, Up 140.74%
Aurinia Pharmaceuticals has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has demonstrated significant growth, with impressive financial metrics, including substantial net sales and profit increases, alongside robust operating cash flow and high institutional holdings.
Is Aurinia Pharmaceuticals, Inc. technically bullish or bearish?
As of July 10, 2025, Aurinia Pharmaceuticals has shifted to a bullish trend, supported by positive MACD, Bollinger Bands, and KST indicators, while outperforming the S&P 500 with a year-to-date return of 43.54% compared to 12.22%.
Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?
As of August 4, 2025, Aurinia Pharmaceuticals is fairly valued with a P/E ratio of 19, slightly below the peer average, and a strong year-to-date return of 43.54%, indicating solid market performance despite its valuation grade moving from attractive to fair.
Aurinia Pharmaceuticals Hits New 52-Week High of $12.90
Aurinia Pharmaceuticals has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has demonstrated significant growth, with a notable return on equity and positive financial results over the past five quarters, highlighting its operational strength and market position.
Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?
As of May 12, 2025, Aurinia Pharmaceuticals is fairly valued with a P/E ratio of 19 and strong growth potential, despite a year-to-date decline of 12.81% compared to the S&P 500's gain of 2.44%, while maintaining impressive operational efficiency with a ROCE of 99.51% and ROE of 16.33%.
Is Aurinia Pharmaceuticals, Inc. technically bullish or bearish?
As of May 1, 2025, Aurinia Pharmaceuticals has a mildly bullish trend, supported by daily moving averages, though weekly MACD and Bollinger Bands indicate short-term weakness; overall, monthly indicators suggest potential for recovery despite recent underperformance against the S&P 500.
Who are in the management team of Aurinia Pharmaceuticals, Inc.?
As of March 2022, the management team of Aurinia Pharmaceuticals, Inc. is led by Dr. George Milne (Independent Chairman) and Mr. Peter Greenleaf (President and CEO), supported by several directors including Dr. Daniel Billen, Mr. R. Hector MacKay-Dunn, Mr. Joseph Hagan, Dr. Michael Hayden, and Dr. David Jayne.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
